[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-peritoneal-clear-cell-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-peritoneal-clear-cell-adenocarcinoma":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100433092","phase-2-apl-2-and-pembrolizumab-versus-apl-2-pembrolizumab-and-bevacizumab-versus-bevacizumab-alone-for-the-treatment-of-recurrent-ovarian-fallopian-tube-or-primary-peritoneal-cancer-and-malignant-effusion-100433092",false,"NCT04919629","APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion","Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion","Inclusion Criteria:\n\n* Age \\>= 18 years of age on day of signing informed consent\n* Recurrent epithelial ovarian\u002Ffallopian tube or primary peritoneal cancer (serous, clear cell, endometrioid, mixed or poorly differentiated or carcinosarcoma) based on imaging or synchronous primary ovarian and uterine cancer patients with any of the histology subtypes mentioned above regardless of platinum sensitivity, prior stage or number of prior treatment lines\n* Symptomatic ascites or pleural effusion or both requiring \\>= 1 drainage within 4-weeks of study entry or has a peritoneal\u002Fpleural drainage catheter in place to control symptoms\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Patient has not received pembrolizumab or other immune checkpoint inhibitor treatment for 9 weeks prior to enrollment\n* Life expectancy of \\>= 3 months\n* Absolute neutrophil count (ANC): \\>= 1,500\u002FµL\n* Platelets: \\>= 75,000\u002FµL\n* Hemoglobin: \\>= 9 g\u002FdL or 5.6 mmol\u002FL (within 7 days of assessment)\n* Creatinine: =\\\u003C 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance \\>= 60 mL\u002Fmin (Cockcroft-Gault Equation) for participant with creatinine levels \\> 1.5 X institutional ULN. GFR can also be used in place of creatinine or creatinine clearance (CrCl)\n* Total bilirubin: =\\\u003C 1.5 X ULN OR direct bilirubin =\\\u003C ULN for participants with total bilirubin levels \\> 1.5 ULN\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]): =\\\u003C 2.5 X ULN OR =\\\u003C 5 X ULN for participants with liver metastases\n* Albumin: \\> 2.5 gm\u002FdL\n* International Normalized Ratio (INR) or Prothrombin Time (PT): =\\\u003C 1.5 unless participant is receiving anticoagulant therapy as long as PT or activated partial thromboplastin time (aPTT) is within therapeutic range of intended use of anticoagulants\n* Activated Partial Thromboplastin Time (aPTT): =\\\u003C 1.5 X ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants\n* A woman of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Participants of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year). Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately\n* Willing and able to self-administer APL-2 (administration by caregiver will be allowed)\n* No known absolute contraindication to bevacizumab and\u002For pembrolizumab treatment per enrolling provider\n* Willing to receive vaccination against Neisseria meningitidis, Streptococcus pneumoniae, and Hemophilus influenzae if randomized into an APL-2 receiving arm, if not already vaccinated\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Is currently receiving any additional cancer therapy or participating or used an investigational drug or device within 3 weeks of the first dose of treatment\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment or, is taking any other medication that might affect immune function\n* Has active autoimmune disease that has required systemic treatment in the past 3 months (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment\n* Has an active infection requiring systemic therapy\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator\n* Participant has clinically significant cardiovascular disease including:\n\n  * Uncontrolled hypertension, defined as systolic \\>150 mmHg or diastolic \\>90 mmHg\n  * Myocardial infarction or unstable angina within 6 months prior to enrollment\n  * New York Heart Association (NYHA) Grade II or greater congestive heart failure\n  * Participant has a Grade II (NYHA) or greater peripheral vascular disease\n  * Participant has a clinically significant peripheral artery disease (e.g. those with claudication), within 6 months prior to study enrollment\n* Pregnancy or lactation\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug\n* Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n* Has a known history of human immunodeficiency virus (HIV) infection\n* Concurrent active hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] positive and\u002For detectable HBV deoxyribonucleic acid \\[DNA\\]) and hepatitis C virus (HCV) (defined as anti-HCV Ab positive and detectable HCV ribonucleic acid \\[RNA\\]) infection. Note: Hepatitis B and C screening tests are not required unless known history of HBV and HCV infection\n* Has received any investigational vaccines (i.e., those not licensed or approved for emergency use). Note: Any licensed COVID-19 vaccine (including for Emergency Use) is allowed in the study as long as they are modified ribonucleic acid (mRNA) vaccines, adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy. Investigational vaccines (i.e., those not licensed or approved for emergency use) are not allowed\n* Known additional malignancy that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded","FEMALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) and a buildup of fluid and cancer cells (malignant effusion). APL-2 may limit tumor progression, decrease malignant effusion production, and improve the immune system's response against cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving APL-2 together with either pembrolizumab or pembrolizumab and bevacizumab may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer and malignant effusion compared to bevacizumab alone.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Fallopian Tube Carcinosarcoma","Fallopian Tube Clear Cell Adenocarcinoma","Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube Serous Adenocarcinoma","Ovarian Carcinosarcoma","Ovarian Clear Cell Adenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Serous Adenocarcinoma","Primary Peritoneal Carcinosarcoma","Primary Peritoneal Clear Cell Adenocarcinoma","Primary Peritoneal Endometrioid Adenocarcinoma","Primary Peritoneal Serous Adenocarcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","RECRUITING","2026-03-19",{"date":44,"type":45},"2026-03-23","ACTUAL",{"date":47,"type":45},"2023-04-27",{"date":49,"type":20},"2028-04-30",{"name":51,"class":52},"Roswell Park Cancer Institute","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100406708","phase-3-minimally-invasive-surgery-after-neoadjuvant-chemotherapy-for-the-treatment-of-stage-iiic-iv-ovarian-primary-peritoneal-or-fallopian-tube-cancer-lance-trial-100406708","NCT04575935","Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial","Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Stage IIIC or IV, high-grade (serous, endometrioid, clear-cell, transitional carcinomas), invasive epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian-tube carcinoma or pathology consistent with high-grade mullerian carcinoma.\n* Patient is considered by treating physician to be a surgical candidate after completion of 3 to 4 cycles of platinum-based chemotherapy, or an investigational neoadjuvant regimen given according to protocol, with complete radiologic resolution of any disease outside the abdominal cavity. Pleural effusions are acceptable per the local PI's discretion.\n* Normalization of CA-125 according to individual participating center reference range (Note: Among patients with a normal CA-125 at initiation of therapy, the CA-125 cannot exceed 35 U\u002FmL at the completion of NACT prior to interval debulking surgery.) or has a CA-125 value ≤500 and is scheduled to undergo a diagnostic laparoscopy prior to debulking surgery. a. For patients undergoing diagnostic laparoscopy, surgeon considers that optimal debulking is feasible either by MIS or laparotomy.\n* Timeframe of \\\u003C 6 weeks (42 days) from the last cycle of NACT to interval debulking surgery. Overall timeframe may be extended per MD Anderson PI discretion.\n* ECOG performance status 0-2\n* Signed informed consent and ability to comply with follow-up\n* Negative pregnancy test by blood or urine (within 14 days prior to surgery)\n* Disease free of other active malignancies in the previous five years, except basal and squamous cell carcinomas of the skin\n\nExclusion Criteria:\n\n* Evidence of tumor not amenable to minimally invasive resection on pre-operative imaging (CT, PET-CT, or MRI) including but not limited to the following findings that may preclude minimally invasive resection per surgeon's assessment. • Failure of improvement of ascites during NACT (trace ascites is allowed) • Small bowel or gastric tumor involvement • Colon or rectal tumor involvement • Diaphragmatic tumor involvement • Splenic or hepatic surface or parenchymal tumor involvement • Mesenteric tumor involvement • Tumor infiltration of the lesser peritoneal sac\n* History of psychological, familial, sociological or geographical condition potentially preventing compliance with the study protocol and follow-up schedule\n* Inability to tolerate prolonged Trendelenburg position or pneumoperitoneum as deemed by participating institution's clinicians\n* Any other contraindication to MIS as assessed by the clinician",{"count":62,"type":20},580,[64],"PHASE3","This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedure that uses small incision(s) and is intended to produce minimal blood loss and pain for the patient. Laparotomy is a surgical procedure which allows the doctors to remove some or all of the tumor and check if the disease has spread to other organs in the body. MIS may work the same or better than standard laparotomy after chemotherapy in prolonging the return of the disease and\u002For improving quality of life after surgery.",[67,27,68,69,70,31,32,33,71,35,36,37,72,73,74,75,76,77,78,79,80,81,82,83,84],"Advanced Ovarian Carcinoma","Fallopian Tube Endometrioid Tumor","Fallopian Tube Serous Neoplasm","Fallopian Tube Transitional Cell Carcinoma","Ovarian Transitional Cell Carcinoma","Primary Peritoneal Transitional Cell Carcinoma","Stage IIIC Fallopian Tube Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8","Stage IVA Fallopian Tube Cancer AJCC v8","Stage IVA Ovarian Cancer AJCC v8","Stage IVA Primary Peritoneal Cancer AJCC v8","Stage IVB Fallopian Tube Cancer AJCC v8","Stage IVB Ovarian Cancer AJCC v8","Stage IVB Primary Peritoneal Cancer AJCC v8","2026-03-03",{"date":87,"type":45},"2026-03-05",{"date":89,"type":45},"2020-08-05",{"date":91,"type":20},"2028-12-31",{"name":93,"class":52},"M.D. Anderson Cancer Center",19,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":5},"100565199","phase-2-folate-receptor-alpha-dendritic-cells-frdcs-or-placebo-for-the-treatment-of-patients-with-stage-iii-or-iv-ovarian-fallopian-tube-or-primary-peritoneal-cancer-farout-trial-100565199","NCT06639074","Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial","MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histological confirmation of Federation of Gynecology and Obstetrics (FIGO) stage III or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. NOTE: Histologic confirmation of the primary tumor is required. Eligible histotypes include high grade serous; endometrioid; and clear cell carcinoma, as these histotypes have high expression of FRα (Kalli, Oberg, Keeney, \\& et al., 2008). Mixed carcinomas, including carcinosarcomas, with ≥ 50% of the tumor comprised of high grade serous; and\u002For endometrioid; and\u002For clear cell carcinoma are eligible\n* Completion of cytoreductive surgery and one (and only one) course of platinum-based chemotherapy (5-9 cycles) ≥ 4 but ≤ 12 weeks prior to registration\n\n  * NOTE: Cytoreductive surgery may have been prior to or after one or more cycles of chemotherapy and must include hysterectomy and bilateral salpingo-oophorectomy (if the uterus and\u002For ovaries were not previously removed)\n  * NOTE: Patients may have had more than one chemotherapy regimen (examples: paclitaxel\u002Fcarboplatin switched to docetaxel\u002Fcarboplatin due to allergy; or weekly treatment switched to every 3-weekly treatment due to intolerance), but may not have received a separate course of treatment for recurrent OC\n  * NOTE: Patients may receive both neoadjuvant and adjuvant chemotherapy provided both regimens are platinum-based and total nine (9) or fewer chemotherapy cycles\n* Germline and somatic genetic testing have been completed\n\n  * NOTE: No pathogenic mutations of BRCA1\u002FBRCA2 are allowed\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Expected survival ≥ 6 months\n* Hemoglobin ≥ 8.5 g\u002FdL (≤ 15 days prior to registration)\n* Absolute neutrophil count (ANC) ≥ 1000\u002Fmm\\^3 (≤ 15 days prior to registration)\n* Platelet count ≥ 75,000\u002Fmm\\^3 (≤ 15 days prior to registration)\n* Lymphocytes ≥ 0.3 x 10\\^9\u002FL (≤ 15 days prior to registration)\n* Monocytes ≥ 0.25 x 10\\^9\u002FL (≤ 15 days prior to registration)\n* Total bilirubin ≤ upper limit of normal (ULN), unless patient has a documented history of Gilbert's disease, then direct bilirubin ≤ ULN (≤ 15 days prior to registration)\n* Aspartate transaminase (AST) ≤ 3 x ULN (≤ 15 days prior to registration)\n* Creatinine clearance ≥ 30 mL\u002Fmin per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation (≤ 15 days prior to registration)\n* Provide written informed consent\n* Willing to provide mandatory blood specimens for correlative research\n* Willing to provide archival tissue specimen for correlative research\n* Willing to return a participating institution for follow-up (during the active monitoring phase of the study)\n* Willing to undergo a tetanus vaccination (if not performed ≤ 365 days prior to registration)\n* Willing to have a central access line placed, if needed (as determined during venous access assessment)\n\nExclusion Criteria:\n\n* Any of the following because this study involves an investigational agent, the genotoxic, mutagenic, and teratogenic effects of which on the developing fetus and newborn are unknown\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential or able to father a child who are unwilling to employ adequate contraception\n* Evidence of disease at the time of registration, including clinical concern for disease recurrence based on each of the following:\n\n  * Evidence of disease by history and physical exam\n  * CA125 outside institutional normal limits\n  * CT (and or MRI) of the chest\u002Fabdomen\u002Fpelvis demonstrating radiological evidence of disease performed after completion of chemotherapy ≤ 28 days be-fore entering study\n* Germline or somatic BRCA1 or BRCA2 mutation, as determined by Clinical Laboratory Improvement Act (CLIA)-approved tests\n* Prior radiation therapy for this cancer\n* Treatment with chemotherapy, angiogenesis inhibitor therapy, poly (ADP-ribose) polymerase (PARP) inhibitor therapy, radiation therapy, or other immunotherapy ≤ 4 weeks prior to registration\n* Receiving any other standard therapy (angiogenesis inhibitor, PARP inhibitor) or investigational agent, which would be considered as a treatment for the primary neoplasm. These agents have been shown to be active in later line therapy and can be used at that time for patients who relapse after treatment on this trial\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n  * EXCEPTIONS: HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. For patients with evidence of hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Other active malignancy ≤ 3 years prior to registration\n\n  * EXCEPTIONS: Patients with non-melanotic skin cancer, papillary thyroid cancer not requiring therapy or carcinoma-in-situ are eligible for this trial. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. (Contact site principal investigator \\[PI\\] if questions.)\n* History of myocardial infarction ≤ 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n\n  * NOTE: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* Treatment with systemic immunosuppressive medication (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[TNF\\]-alpha agents) ≤ 2 weeks prior to registration, or anticipation of need for systemic immunosuppressive medication during the course of the study\n\n  * NOTE: Patients who have received acute, low-dose systemic steroids (≤ 10 mg\u002Fday oral prednisone or equivalent) prior to registration or a one-time pulse dose of systemic immunosuppressant medication (e.g., ≤ 48 hours of corticosteroids for a contrast allergy) are eligible for the study\n  * NOTE: The use of inhaled corticosteroids for chronic obstructive pulmonary disease or asthma, mineralocorticoids (e.g., fludrocortisone), or low-dose corticosteroids for patients with orthostatic hypotension or adrenocortical insufficiency is allowed",{"count":103,"type":20},78,[23],"This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopian tube or primary peritoneal cancer. FRαDCs, a dendritic cell vaccine, is made from a person's white blood cells. The white blood cells are treated in the laboratory to make dendritic cells (a type of immune cell) mixed with folate receptor alpha (FRalpha), a protein found in high levels on ovarian tumor cells. FRαDCs work by boosting the immune system to recognize and destroy the tumor cells by targeting the FRalpha protein on the tumor cell. Placebo is an inactive substance that looks the same as, and is given the same way as, the active drug or treatment being tested. The effects of the active drug are compared to the effects of the placebo. Giving FRαDCs may work better in preventing or delaying recurrence compared to placebo in patients with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.",[107,108,67,109,110,111,112,113,114,26,27,28,115,116,117,34,35,36],"Advanced Fallopian Tube Carcinoma","Advanced Fallopian Tube High Grade Serous Adenocarcinoma","Advanced Ovarian Carcinosarcoma","Advanced Ovarian Clear Cell Adenocarcinoma","Advanced Ovarian Endometrioid Adenocarcinoma","Advanced Ovarian High Grade Serous Adenocarcinoma","Advanced Primary Peritoneal Carcinoma","Advanced Primary Peritoneal High Grade Serous Adenocarcinoma","FIGO Stage III Ovarian Cancer 2014","FIGO Stage IV Ovarian Cancer 2014","Ovarian Mixed Cell Adenocarcinoma","2025-09-29",{"date":120,"type":45},"2025-10-02",{"date":122,"type":45},"2024-11-08",{"date":124,"type":20},"2027-12-31",{"name":126,"class":52},"Mayo Clinic"]